Home / Healthcare / Healthcare News In Focus: Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC)

Healthcare News In Focus: Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC)

Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, declares the appointment of Jeffrey A. Meckler as Chief Executive Officer, effective right away. Mr. Meckler was named Vice Chairman of the Intec Pharma Board of Directors in April 2017 and will continue in that role. Giora Carni, a Director since 2006 who has served as Interim Chief Executive Officer since May 2017, will continue to serve on the company’s Board.
“In the few months Jeffrey has been on the Intec Board he established himself as a strong, insightful leader and made noteworthycontributions to our company. We are delighted to appoint him as Chief Executive Officer and extend thanks to Giora for stepping in to serve as interim CEO,” commented John W. Kozarich, Ph.D., Chairman of the Board of Intech Pharma.
“We look forward to building a U.S. presence under Jeffrey’s stewardship while advancing our Accordion Pill platform technology in a number of therapeutic indications. In particular, as we near the completion of a pivotal Phase 3 clinical trial of our Accordion Pill Carbidopa/Levodopa, Jeffrey’s considerable industry experience should enhance our pre-commercialization strategies to maximize the potential of the Accordion Pill in Parkinson’s disease,” he added. “Importantly, Jeffrey’s planned planning and business development skills make him exclusively qualified to expand our platform technology in various indications and to enhance the industry’s recognition of our gastric retention drug delivery technology.”
Mr. Meckler has more than 25 years of life sciences executive experience. He spent more than 17 years at Pfizer, where he held leadership positions in corporate planned planning, acquisitions and business development, market research, manufacturing systems and sales operations analysis. Most recently he was Chief Executive Officer of Cocrystal Pharma, Inc. Formerly, Mr. Meckler was a director of QLT Inc., and at first the principal executive officer during its transformation into an orphan drug company. He has served on numerous corporate boards and is presently a director of Retrophin, Inc.
“I am honored to be named CEO of Intec Pharma at this pivotal point in our company’s development,” said Mr. Meckler. “We face noteworthyopportunities with our late-stage program in Parkinson’s disease. In addition we have a versatile platform technology that can improve the efficacy and safety of existing and development-stage drugs by utilizing a proprietary gastric retention mechanism. I look forward to working with our team in Israel and to establishing a footprint in the U.S. Together we will execute a broad development program for the Accordion Pill technology that will allow us to build value for our shareholders and ensure the success of our company.”
Mr. Meckler earned his J.D. from Fordham University School of Law and is admitted to the New York Bar. He earned an M.S. in Industrial Administration and a B.S. in Industrial Administration from Carnegie Mellon University’s Tepper School of Business.

Check Also

News Recap: Twitter, Inc. (NYSE: TWTR)

Twitter, Inc. (NYSE: TWTR) recently declared the appointment of Ned Segal as Chief Financial Officer …